These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30447706)

  • 21. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
    Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
    Li R; Liu GZ; Luo SY; Chen R; Zhang JX
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.
    Wang W; Shi Y; Li J; Cui W; Yang B
    Biosci Rep; 2016; 36(2):. PubMed ID: 27128470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of MDR1 gene (C3435T) polymorphism and gene expression profiling in lung cancer patients treated with platinum-based chemotherapy.
    Subhani S; Jamil K; Nirni SS
    Mol Diagn Ther; 2015 Oct; 19(5):289-97. PubMed ID: 26288241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.
    Yu ZW; Zhong LP; Ji T; Zhang P; Chen WT; Zhang CP
    Oral Oncol; 2010 Apr; 46(4):317-22. PubMed ID: 20219416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Single Nucleotide Polymorphisms (rs1292037 and rs13137) in miR-21 Were Associated with T2DM in a Chinese Population.
    Li Y; Yang J; Tao W; Yang M; Wang X; Lu T; Li C; Yang Y; Yao Y
    Diabetes Metab Syndr Obes; 2022; 15():189-198. PubMed ID: 35087281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
    Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
    [No Abstract]   [Full Text] [Related]  

  • 28. [The guidelines for diagnostics and treatment of cervical cancer].
    Inciūra A; Juozaityte E
    Medicina (Kaunas); 2004; 40(4):394-403. PubMed ID: 15111756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer.
    Kawano M; Mabuchi S; Matsumoto Y; Sasano T; Takahashi R; Kuroda H; Kozasa K; Hashimoto K; Isobe A; Sawada K; Hamasaki T; Morii E; Kimura T
    Sci Rep; 2015 Dec; 5():18217. PubMed ID: 26666576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.
    Yuan F; Sun R; Chen P; Liang Y; Ni S; Quan Y; Huang J; Zhang L; Gao L
    Tumour Biol; 2016 May; 37(5):6267-73. PubMed ID: 26619844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
    Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
    Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study.
    Yang Z; Chen D; Zhang J; Yao D; Gao K; Wang H; Liu C; Yu J; Li L
    Gynecol Oncol; 2016 May; 141(2):231-239. PubMed ID: 26115978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).
    Ohnishi S; Watari H; Kanno M; Ohba Y; Takeuchi S; Miyaji T; Oyamada S; Nomura E; Kato H; Sugiyama T; Asaka M; Sakuragi N; Yamaguchi T; Uezono Y; Iwase S
    J Gynecol Oncol; 2017 Sep; 28(5):e44. PubMed ID: 28657216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cisplatin plus paclitaxel as chemotherapy in patients with cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on immune function.
    Zhang J; Song C; Liu B
    Pak J Pharm Sci; 2022 Jan; 35(1(Special)):355-359. PubMed ID: 35236647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curative effect of paclitaxel and cisplatin combined chemotherapy on cervical cancer and its relation with tissue micro vascular and lymphatic vessels density.
    Gao ZH; Wang QQ
    Pak J Pharm Sci; 2015 Sep; 28(5 Suppl):1849-52. PubMed ID: 26525017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma.
    Cheng MW; Shen ZT; Hu GY; Luo LG
    Cell Physiol Biochem; 2017; 42(2):660-672. PubMed ID: 28618418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Long Non-coding RNA (LncRNA) in the Pathogenesis of Chemotherapy Resistance in Cervical Cancer: Diagnostic and Prognostic Approach.
    Modabber N; Mahboub SS; Khoshravesh S; Karimpour F; Karimi A; Goodarzi V
    Mol Biotechnol; 2024 Oct; 66(10):2751-2768. PubMed ID: 37804407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency.
    Rah H; Kim HS; Cha SH; Kim YR; Lee WS; Ko JJ; Kim NK
    Menopause; 2015 Apr; 22(4):437-43. PubMed ID: 25203895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. USF1 gene polymorphisms may associate with the efficacy and safety of chemotherapy based on paclitaxel and prognosis in the treatment of ovarian cancer.
    Ye H; Liu XJ; Hui Y; Liang YH; Li CH; Wan Q
    Neoplasma; 2018; 65(1):153-160. PubMed ID: 29322800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.